Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEWTBVAC

Financiado

Cerrado

Discovery and preclinical development of new generation tuberculosis vaccines

With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and... ver más

28/02/2014

TBVI

19M€

Presupuesto del proyecto: 19M€

Líder del proyecto

STICHTING TUBERCULOSIS VACCINE INITIATIVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 31 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-02-28 No tenemos la información de la convocatoria

0% 63% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

31 Participantes

TBVI

0.00€ | Lider

ASTON U

N.D. | Participante

CNRS

N.D. | Participante

KANTONSSPITAL BASEL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Slow growth Deciphering the molecular mechanism s behind the evolution... 185K€ Cerrado

ITHEMYC Novel immunotherapies for tuberculosis and other mycobacteri... 5M€ Cerrado

STriTuVaD In Silico Trial for Tuberculosis Vaccine Development 5M€ Cerrado

TBVAC-HORIZON Improving understanding of lung immunity in tuberculosis to... 7M€ Cerrado

IMAGING TB Deciphering mycobacterial subversion of early steps of adapt... 269K€ Cerrado

ESI-TBVI Establishment Strategy and Initial activities of the TuBerc... 520K€ Cerrado

Líder del proyecto

STICHTING TUBERCULOSIS VACCINE INITIATIVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 19M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current control measures the Millennium Development Goals (MDGs) set for 2015 may be achieved, reaching these would still leave a million people per year dying from TB. Much more effective measures, particularly more effective vaccines will be essential to reach the target of eliminating TB in 2050. Two successive FP5 and FP6 funded projects, Tuberculosis (TB) Vaccine Cluster (2000-2003) and TBVAC (2004-2008), have in the recent decade made significant contributions to the global TB vaccine pipeline, with four vaccines (out of nine globally) being advanced to clinical stages. Both projects strongly contributed to the strengthening and integration of expertise and led to a European focus of excellence that is unique in the area of TB vaccine development. In order to sustain and accelerate the TB vaccine developments and unique integrated excellence of TBVAC, a specific legal entity was created named TuBerculosis Vaccine Initiative (TBVI). The NEWTBVAC proposal is the FP7 successor of TBVAC, and will be coordinated by TBVI. The proposal has the following objectives : 1) To sustain and innovate the current European pipeline with new vaccine discoveries and advance promising candidates to clinical stages; 2) To design new, second generation vaccines based new prime-boost strategies and/or new (combinations of) promising subunit vaccines, that will impact on reduction of disease in exposed individuals; 3) To sustain and innovate discovery, evaluation and testing of new biomarkers, that will be critically important for future monitoring of clinical trials.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores